Dxd(Exatecan derivative for ADC) is an effective DNA topoisomerase I inhibitor with IC50 of 0.31 μM. DXD can be used to make antibody drug conjugate such as Trastuzumab Deruxtecan (DS-8201a).

 

Brand: BCM

 

Signaling Pathways: DNA Damage/DNA Repair

 

Target: Topoisomerase I:0.31 μM

Solubility: DMSO: 50 mg/mL (101.32 mM), Need ultrasonic. Insoluble in Water; insoluble in Ethanol.

 

Isomeric SMILES: CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=C5[C@H](CCC6=C5C(=CC(=C6C)F)N=C4C3=C2)NC(=O)CO)O  

 

InChIKey: PLXLYXLUCNZSAA-QLXKLKPCSA-N  

 

InChI: InChI=1S/C26H24FN3O6/c1-3-26(35)15-6-19-23-13(8-30(19)24(33)14(15)10-36-25(26)34)22-17(28-20(32)9-31)5-4-12-11(2)16(27)7-18(29-23)21(12)22/h6-7,17,31,35H,3-5,8-10H2,1-2H3,(H,28,32)/t17-,26-/m0/s1  

 

Attribute
[Chem Name]	N-[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]-2-hydroxyacetamide
[Synonym]	Dxd
[CAS No.]	1599440-33-1
[MDL No.]	MFCD31657444
[Formula]	C26H24FN3O6
[Molecular]	493.48
[Form]	Solid powder
[Storage]	Sealed in dry,2-8°C

Goods Tag